Eris Lifesciences Ltd
NSE:ERIS

Watchlist Manager
Eris Lifesciences Ltd Logo
Eris Lifesciences Ltd
NSE:ERIS
Watchlist
Price: 1 371.55 INR 4.32% Market Closed
Market Cap: 186.8B INR

Eris Lifesciences Ltd
Investor Relations

Nestled in the competitive landscape of India's pharmaceutical sector, Eris Lifesciences Ltd. has carved a niche for itself by focusing intently on the domestic market, predominantly within the specialty prescription segment. Founded in 2007 by Amit Bakshi, the company has distinguished itself with a strategy that emphasizes building relationships with medical professionals through a robust field force, eschewing the conventional tactic of overwhelming physicians with a vast army of generic products. Eris opts for precision, targeting chronic and lifestyle-related ailments such as diabetes, cardiology, and neurology. This focus on long-term therapies aligns with the rising demand for healthcare tailored to the aging population's needs and the increase in lifestyle diseases in India, thus ensuring a steady stream of revenue.

The brilliance of Eris Lifesciences' business model is reflected in its comprehensive distribution network and a well-coordinated supply chain that covers a significant portion of Indian urban centers. By manufacturing many of its products in-house, Eris maintains control over production quality and cost – a strategic move that bolsters its pricing power in the competitive generics market. The company also adeptly tweaks its offerings and strategies based on physician feedback and market trends, ensuring relevance and resonance with its target segments. This model is not about flooding the market with a plethora of offerings; it's about precision placement with specialized therapeutic products that meet specific, high-demand needs – a strategy that has consistently translated into tangible financial growth.

Show more
Loading

Earnings Calls

2024 Q4
Jan 21, 2025
Show Transcript
Previous
Next
Strong Fourth Quarter Performance Sets Positive Outlook for 2025
2024 Q4
Jan 21, 2025

In the fourth quarter, the company reported a 49% increase in GAAP earnings per share to $0.94, driven by strong revenue growth of 10.8% year-over-year. Total operating revenues reached $196 million, with net interest income up 9.9%. For 2025, the company anticipates mid- to high single-digit revenue growth and expects to add 16 new branches, leading to some short-term expense increases. Despite competitive pressures, a robust liquidity position and the expectation of continued net interest income expansion underpin an optimistic outlook for maintaining market share and profitability.

Show Full Analysis

Management

Mr. Amit Indubhushan Bakshi
Chairman & MD
No Bio Available
Mr. Sachin Shah
Chief Financial Officer
No Bio Available
Mr. Krishnakumar Vaidyanathan
Executive Director & COO
No Bio Available
Mr. Gagan Atreja
President of Sales & Marketing
No Bio Available
Mr. Inderjeet Singh Negi
Executive Director
No Bio Available
Mr. Kaushal Kamlesh Shah
Whole Time Director
No Bio Available
Mr. Deepak Kapoor
Senior Vice President
No Bio Available
Mr. Milind Talegaonkar
Compliance Officer & Company Secretary
No Bio Available
Mr. Vijay S. Joshi
President Medical
No Bio Available
Mr. Manish Kapoor
Vice President
No Bio Available

Contacts

Address
GUJARAT
Ahmedabad
8th Floor, Commerce House- IV,, Prahladnagar, 100 ft road
Contacts
+917930451111
www.eris.co.in